Societal cost of cancer in Norway –Results of taking a broader cost perspective

Bugge, Christoffer; Sæther, Erik Magnus; Brustugun, Odd Terje; Kristiansen, Ivar Sønbø

doi:10.1016/j.healthpol.2021.05.008

Cited by 12 publications

(11 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…renal pelvis), or urinary tract or with melanoma of the skin, non-Hodgkin lymphoma, leukemia or multiple myeloma. In cases where patients had multiple cancer diagnoses, diagnosis was assigned based on the most frequently listed diagnosis [23] . Additionally, all cancers (C00-99, D00-09, D37-48) were evaluated together.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Phase- and gender-specific, lifetime, and future costs of cancer

Bugge

Brustugun

Sæther³

et al. 2021

Medicine

Self Cite

View full text Add to dashboard Cite

Valid estimates of cancer treatment costs are import for priority setting, but few studies have examined costs of multiple cancers in the same setting. We performed a retrospective population-based registry study to evaluate phase-specific (initial, continuing, and terminal phase) direct medical costs and lifetime costs for 13 cancers and all cancers combined in Norway. Mean monthly cancer attributable costs were estimated using nationwide activity data from all Norwegian hospitals. Mean lifetime costs were estimated by combining phase-specific monthly costs and survival times from the national cancer registry. Scenarios for future costs were developed from the lifetime costs and the expected number of new cancer cases toward 2034 estimated by NORDCAN. For all cancers combined, mean discounted per patient direct medical costs were Euros (EUR) 21,808 in the initial 12 months, EUR 4347 in the subsequent continuing phase, and EUR 12,085 in the terminal phase (last 12 months). Lifetime costs were higher for cancers with a 5-year relative survival between 50% and 70% (myeloma: EUR 89,686, mouth/pharynx: EUR 66,619, and non-Hodgkin lymphoma: EUR 65,528). The scenario analyses indicate that future cancer costs are highly dependent on future cancer incidence, changes in death risk, and cancer-specific unit costs. Gender- and cancer-specific estimates of treatment costs are important for assessing equity of care and to better understand resource consumption associated with different cancers. Cancers with an intermediate prognosis (50%–70% 5-year relative survival) are associated with higher direct medical costs than those with relatively good or poor prognosis.

show abstract

Section: Methodsmentioning

confidence: 99%

“…In cases where patients had multiple cancer diagnoses, diagnosis was assigned based on the most frequently listed diagnosis. [23] Additionally, all cancers (C00-99, D00-09, D37-48) were evaluated together.…”

Section: Patient Classificationmentioning

confidence: 99%

Phase- and gender-specific, lifetime, and future costs of cancer

Bugge

Brustugun

Sæther³

et al. 2021

Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Such estimates for other countries have not been published. We estimate the cost per MG patient per year at EU 24,743, while similar estimates are EUR 84,894 for cancer [11] and EUR 7583 for migraine [23]. MG patients in Norway have a relatively high share of inpatient stays compared to the number of primary care visits and outpatient stays at hospitals.…”

Section: Discussionmentioning

confidence: 99%

“…This includes informal care costs and lost productivity due to reduced working ability. In the case of other disease areas, such as cancer, informal care costs have been estimated to account for 10.1% of the total productivity losses [11]. Costs related to reduced working ability have been estimated to account for 39.5% of the productivity losses related to migraines [23].…”

Section: Discussionmentioning

confidence: 99%

“…MG-related drug prescriptions for our sample of MG patients were identified by ATC codes (Table S6). We used Diagnosis Related Group (DRG) cost weights, reimbursement fees, patient co-payments, and drug prices (excluding VAT), following a methodology similar to that used by Bugge et al [11]. Patient travel costs associated with treatment were derived from the literature [12] and adjusted for inflation.…”

Section: Direct Costsmentioning

confidence: 99%

See 1 more Smart Citation

The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data

Engebretsen,

Gilhus,

Kristiansen

et al. 2024

Euro J of Neurology

Self Cite

View full text Add to dashboard Cite

Background and purposeWith the emergence of new treatment options for myasthenia gravis (MG), there is a need for information regarding epidemiology, healthcare utilization, and societal costs to support economic evaluation and identify eligible patients. We aimed to enhance the understanding of these factors using nationwide systematic registry data in Norway.MethodsWe received comprehensive national registry data from five Norwegian health‐ and work‐related registries. The annual incidence and prevalence were estimated for the period 2013–2021 using nationwide hospital and prescription data. The direct, indirect (productivity losses) and intangible costs (value of lost life‐years [LLY] and health‐related quality of life [HRQoL]) related to MG were estimated over a period of 1 year.ResultsIn 2021, the incidence of MG ranged from 15 to 16 cases per year per million population depending on the registry used, while the prevalence varied between 208.9 and 210.3 per million population. The total annual societal costs of MG amounted to EUR 24,743 per patient, of which EUR 3592 (14.5%) were direct costs, EUR 8666 (35.0%) were productivity loss, and EUR 12,485 (50.5%) were lost value from LLY and reduced HRQoL.ConclusionThe incidence and prevalence of MG are higher than previously estimated, and the total societal costs of MG are substantial. Our findings demonstrate that productivity losses, and the value of LLY and HRQoL constitute a considerable proportion of the total societal costs.

show abstract